Geron Corporation (NASDAQ:GERN) announced its 2026 outlook on January 12, projecting RYTELO (imetelstat) revenue between $220 million and $240 million. The company expects operating expenses to range from $230 million to $240 million after a recent restructuring.
The blood-cancer-focused biopharmaceutical firm anticipates stronger growth in the second half of the year as it increases outreach to physicians and patients. Geron is prioritizing U.S. commercialization, international expansion, and progress in its Phase 3 IMpactMF trial.
RYTELO, a first-in-class telomerase inhibitor approved in the U.S. and European Union for lower-risk MDS-related anemia, continues to build clinical support. New IMerge data was presented at the 2025 ASH meeting.
On December 16, the company began a restructuring drive to achieve profitability in the second half of 2026. Geron is trimming its workforce by nearly a third, a move expected to reduce operating expenses but likely to result in $18 million in restructuring charges for severance payments and healthcare benefits.
In addition to cost cuts, the company plans to focus on expanding U.S. commercial sales while pursuing international opportunities in Europe for its key products.
"Our key objectives remain unchanged," said Harout Semerjian, President and Chief Executive Officer of Geron. "We are focused on driving RYTELO commercial growth in the U.S., exploring opportunities for making RYTELO available outside the U.S., and continuing to advance our Phase 3 IMpactMF trial. We expect this restructuring will have a meaningful impact on our 2026 operating expenses and position Geron to meet the needs of patients."
The company also amended its loan agreement with Pharmakon Advisors, securing access to up to $125 million through July 2026.